Sign in to sync your peptides securely across your devices.
New here?
Peptrail is invite-only right now. Tell us a bit about you and we'll send an invite if it's a fit.
Your time-of-day headers — e.g. rename these to Rise, Fuel, Rest. Supplements you add get grouped under whichever section you pick.
Retatrutide is the first compound to hit three metabolic receptors at once — GLP-1, GIP, and glucagon. In Phase 3 trials it produced the largest weight reduction ever reported for a drug in this class, alongside improvements in blood sugar, blood pressure, cholesterol, and joint pain. It is also the most powerful compound most people will ever consider, and it is not approved anywhere in the world.
Retatrutide is a 39-amino-acid peptide developed by Eli Lilly. Where semaglutide activates one receptor and tirzepatide activates two, retatrutide activates three: GLP-1, GIP, and glucagon. That third receptor is what makes it different — and it's the reason the weight loss numbers are larger than anything before it.
It is investigational. As of mid-2026 it has completed several Phase 3 trials with strong results, but it is not approved by the FDA, the EMA, or any other regulator, and there is no prescription pathway for it anywhere.
| Benefit | Description |
|---|---|
| Weight reduction | The largest effect reported for any drug in this class — up to roughly 28–30% of body weight in Phase 3 trials at the highest dose. |
| Blood sugar | Lowers HbA1c and fasting glucose; improves insulin sensitivity. Studied specifically in type 2 diabetes. |
| Cardiometabolic markers | Reduced triglycerides, non-HDL cholesterol, systolic blood pressure, waist circumference, and inflammatory markers. |
| Joint pain | In people with obesity and knee osteoarthritis, substantial reductions in pain scores and improved physical function. |
| Appetite regulation | Pronounced reduction in food intake and food-related preoccupation through combined GLP-1 and GIP signaling. |
| Energy expenditure | The glucagon arm increases metabolic rate and drives fat mobilization — the mechanism the other drugs in this class don't have. |
Three receptors, three jobs, one molecule.
Slows stomach emptying, increases satiety through the hypothalamus, and boosts glucose-dependent insulin release. This is the appetite arm.
Works alongside insulin to help cells take up blood sugar and use it for energy. Also appears to reduce nausea signalling, which is part of why dual agonists tolerate better than expected.
Raises energy expenditure and mobilizes stored fat, particularly in the liver. This is the arm that's unique to retatrutide.
The first two reduce how much energy comes in. The third increases how much goes out. Attacking both sides at once is why the effect size exceeds compounds that only do the first part.
Your body is like a busy little town.
Day and night it has important jobs to do. There's an energy factory turning your food into fuel, a fuel station keeping your levels just right, and a hunger center that tells you when it's time to eat.
To get all those jobs done, your body sends out tiny messengers, like little mail carriers zipping around with notes. The notes say things like "Time to eat!" or "You're full!" or "Use this fuel!" Grown-ups call these messengers hormones.
The "You're full!" note might show up too late — so your tummy keeps asking for more, even when it already has plenty.
Or your body holds onto extra fuel and tucks it away, instead of using it up.
Here's the really cool part. It's like one super-letter that can knock on three mailboxes at once.
Those three mailboxes belong to three helpers your body already knows. Retatrutide wakes them up and says, "Let's get to work!"
She taps your brain on the shoulder and says, "You're full now — you can stop. Nice work!"
She also tells your tummy to empty s·l·o·w·l·y, like a bathtub draining one drip at a time. Your food stays cozy in there longer, so you stay full longer and don't get hungry again so fast.
When you eat, your food turns into a kind of sugar-fuel that floats in your blood. Her job is making sure it doesn't just pile up there.
So she calls in a special tool: insulin, which works just like a key. It unlocks tiny doors on your cells so the sugar-fuel can hop inside and give them energy. The Sugar Sorter makes sure the right number of keys show up at exactly the right time.
This one is extra special, because not every medicine has it. His job is to turn up your body's engine, so you burn more fuel — even when you're sitting still.
Think of your body like a campfire. The Engine Spark is a little puff of air that makes the fire burn brighter and warmer, using up extra fuel your body had tucked away for later. More burning means more energy used up. Whoosh!
Now your body has a whole team working together: "You're full!" "Fuel, this way!" "Burn it bright!"
Retatrutide is usually a tiny shot, just once a week. It doesn't work all at once, like flipping a light switch. It works slowly and gently, turning a dial little by little over many weeks. Slow and steady wins the race.
Retatrutide is a helper, not a magic wand. It works best alongside the everyday good stuff — good food, moving your body, plenty of sleep.
And there's one more thing worth knowing. When the Engine Spark is burning through the town's stored fuel this fast, the town still has workers who need feeding. The Fullness Friend is very good at her job now — good enough that the town can end up short on what it genuinely needs.
So the three helpers do their part. And you do yours. That's teamwork.
Retatrutide is not approved anywhere in the world. It has strong Phase 3 data and Lilly is pursuing approval, but as of now there is no regulator-reviewed label, no approved dose, and no prescription pathway. Every non-trial use is happening outside that system.
The trials were run with clinical supervision, structured dose escalation, dietary guidance, and monitoring. Those things aren't incidental to the results — dropping them changes both the safety picture and the outcome.
Losing a quarter of your body weight means losing lean mass too unless protein intake and resistance training are deliberate. This is the most common way people get a bad outcome from a good result.
Side effect rates climb sharply with dose. Trials stepped up every four weeks. Rushing is the single biggest driver of a miserable experience.
In the CV outcomes trial, major cardiac events were numerically similar between drug and placebo, with a wide confidence interval. Risk factors improved; events did not.
A consistent class effect, and the glucagon arm adds to it. Worth knowing your baseline.
Fast weight reduction from any cause raises gallbladder risk. This produces some of the fastest loss ever recorded.
Appetite returns. Regain after discontinuation is well documented across this whole drug class. There's no exit plan built into the vial.
This is the compound where foundations matter most, and it's the one people most often skip them on. Retatrutide makes you eat less — that's the point. But eating less doesn't reduce what your body still requires. It just makes it harder to get.
The single most important one. Appetite suppression this strong plus rapid weight loss will cost you muscle unless protein intake is deliberate and prioritized in every meal you do eat.
Eating far less means taking in far less sodium, potassium, and magnesium — and GI losses compound it. Fatigue, headaches, dizziness and cramps in the first weeks are frequently this, not the drug itself.
Thirst cues drop along with hunger cues. Dehydration is common and makes every other side effect feel worse.
The glucagon arm increases energy expenditure while intake falls. Running very low carbohydrate on top of that is a reliable route to feeling flat and losing training quality.
Slowed gastric emptying plus reduced food volume makes constipation one of the most common complaints. Easier to prevent than to fix.
Not a nutrient, but it belongs here. It's the strongest lever you have for keeping the weight you lose from being muscle.
Retatrutide has more human trial data behind it than anything else in this library. The TRIUMPH program spans eight Phase 3 trials plus a cardiovascular outcomes study.
Unlike most compounds in this library, you will notice this one. Food stops being interesting. The mental chatter about eating quiets down — people describe it as the loudest and strangest part. Meals end early and stay ended.
The first two weeks after each dose increase are usually the hardest. Nausea, unpredictable digestion, and a general flatness are common while the body adjusts, and they typically settle before the next step up.
| Phase | Trial protocol |
|---|---|
| Starting dose | 2 mg weekly |
| Escalation | Every 4 weeks |
| Maintenance doses studied | 4, 9, or 12 mg weekly |
| Time to full dose | Several months |
| Trial duration | 68–104 weeks |
| Half-life | ~6 days |
Stable long-term until reconstituted.
Refrigerate at 2–8°C. With weekly dosing a vial lasts a while, so date the label.
Swirl to dissolve. Agitation damages peptides.
Clear solution only. Cloudiness or particulates mean don't use it.
Gastrointestinal effects dominate, and they scale with dose. From the Phase 3 diabetes trial, rates at 4 mg / 9 mg / 12 mg versus placebo:
| Effect | 4 / 9 / 12 mg vs placebo |
|---|---|
| Diarrhea | 27% / 34% / 34% vs 13% |
| Nausea | 14% / 21% / 28% vs 8% |
| Constipation | 14% / 16% / 17% vs 9% |
| Vomiting | 6% / 10% / 16% vs low |
| Decreased appetite | 6% / 12% / 17% vs 5% |
Most of these are worst in the weeks following a dose increase and settle as the body adjusts. Slower escalation is the main lever. Also reported across trials: increased heart rate, and skin sensitivity at higher doses.
Severe or persistent abdominal pain, especially radiating to the back (possible pancreatitis). Persistent vomiting with an inability to keep fluids down. Signs of gallbladder trouble — pain under the right ribs, fever, yellowing of the skin or eyes.
Retatrutide has no approved pharmaceutical version, which means everything available is a research compound. Given how potent it is, what's in the vial matters more here than almost anywhere.
Lot number should match your vial. A generic PDF reused across the catalog isn't a COA.
The actual chart, not a "99%" claim on a graphic.
Purity tells you how much of one thing is in there. Mass spec tells you it's the right thing. Both matter.
Reported in EU/mg, typically under 0.1. Frequently omitted.
No — not in the US, EU, or anywhere else. Phase 3 trials have completed successfully and Lilly is pursuing approval, but there is currently no approved label and no prescription pathway.
Semaglutide hits one receptor, tirzepatide hits two, retatrutide hits three. The third — glucagon — raises energy expenditure rather than just lowering intake. That's why the weight loss is larger, and part of why the GI side effects are too.
Once weekly in every trial. The half-life is around six days. Charts listing it several times per week don't match how it was studied.
Some, unless you work at not doing so. Losing 25–30% of body weight always includes lean mass. Prioritizing protein and resistance training are the two things that meaningfully change that ratio.
Appetite returns and regain is common — well documented across this entire drug class. Worth thinking about before starting, not after.
Often electrolytes, hydration, or simply not eating enough protein rather than the compound itself. Increasing the dose in response to feeling flat usually makes it worse.
MOTS-c may improve insulin sensitivity, shift the body toward burning fat for fuel, and expand mitochondrial capacity — the machinery behind endurance and metabolic flexibility. It works through AMPK, the same pathway exercise activates. Your body makes it every time you train, and it makes less of it every year.
MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial genome rather than nuclear DNA — one of a small family called mitochondria-derived peptides, alongside humanin and the SHLPs. It was identified in 2015 by Pinchas Cohen's lab at USC.
It behaves like a hormone your mitochondria release. When cells are under energy demand or metabolic stress, MOTS-c signals through AMPK to change how the body handles glucose and fat.
| Benefit | Description |
|---|---|
| Metabolic function | Improves how cells take up and clear glucose, supporting insulin sensitivity and steadier blood sugar. |
| Fat metabolism | Shifts cells toward burning fatty acids for fuel, improving metabolic flexibility — the ability to switch between fuel sources cleanly. |
| Mitochondrial capacity | Signals existing mitochondria to grow and divide, expanding long-term energy capacity through the same pathway endurance training uses. |
| Physical performance | Associated with better endurance and physical output, most clearly in aerobic work rather than strength. |
| Inflammation | Dampens chronic low-grade inflammatory signaling of the kind linked to aging and metabolic dysfunction. |
| Healthy aging | Targets the age-related decline in your own MOTS-c levels, which tracks with reduced metabolic flexibility and exercise capacity. |
AMPK — AMP-activated protein kinase — is the enzyme cells use to sense low energy and respond to it. It's often called the metabolic master switch because it governs how cells produce, store, and spend energy.
MOTS-c doesn't switch AMPK on directly. It interferes with the folate cycle, causing a molecule called AICAR to accumulate — and AICAR activates AMPK.
Cells pull in more glucose through GLUT4 transporters, supporting insulin sensitivity.
Cells shift toward burning fatty acids for fuel.
Through PGC-1α, existing mitochondria grow and divide — the same pathway endurance training uses.
The chronic low-grade kind associated with metabolic dysfunction.
MOTS-c also travels into the nucleus under stress, where it influences genes tied to antioxidant defense — the retrograde signal, mitochondria reporting their state back to the cell's control center.
Think of a cell as a ship.
Deep down in the hull are the engine rooms — the mitochondria. They burn fuel and make all the power the ship runs on. Way up top is the control room, where the decisions get made.
When the engines start running low, they send a runner up to the control room. That runner is MOTS-c.
The message is simple: stop burning through the easy fuel. Start using what we've got stored away — and we need more engine capacity down here.
The control room listens. The ship starts pulling sugar out of the bloodstream and burning stored fat instead. And the engine rooms begin to grow and split into more engine rooms — they don't get built from scratch, they divide, a bit like the bacteria they descended from.
Your engines send that runner every time you exercise. As the ship gets older, they send fewer of them.
Existing mitochondria change what they burn. That's a switch, and it flips quickly.
Mitochondria growing and dividing takes time. This is the part people actually want, and it can't be rushed.
Most of what's known about MOTS-c comes from cell cultures and animal studies. The mechanism is unusually well mapped for a research peptide — understood down to specific genes — but MOTS-c itself has never been through a human clinical trial.
The closest human data comes from CB4211, a synthetic MOTS-c analog that completed Phase 1. About 20 overweight subjects dosed daily for 30 days: blood sugar and liver enzymes improved, body weight did not change.
Cell and rodent studies tell you a compound can do something. Only human trials tell you it does.
It instructs your body to build and burn. Without raw materials, people commonly feel worse before better.
AMPK and mTOR run inversely. Strong AMPK activation dampens muscle-building signaling.
AMPK activators fall under WADA's metabolic modulators category.
Some evidence suggests men may respond more than women. Barely studied.
Every number in circulation comes from practice and inference, not a trial that tested it.
Degrades faster than most. Storage and sourcing matter more than usual.
This is the part most guides skip. MOTS-c doesn't supply energy — it instructs your cells to build capacity and change how they burn fuel. Those instructions require raw materials. Signal your body to expand mitochondrial capacity without supplying what that takes, and a plausible outcome is feeling worse rather than better.
AMPK activation increases glucose uptake. Running this pathway hard while low on fuel is a straightforward way to feel flat.
Not a supporting nutrient — an actual physical component of the electron transport chain. Absorption is better with fat.
A cofactor for most ATP-dependent enzymes. ATP functions as Mg-ATP; without magnesium it's largely inert.
The molecule the electron transport chain runs on. NAD+ itself is poorly absorbed orally — NR or NMN are the usual route.
Mitochondria are largely protein. Building more draws on the same amino acid pool as everything else.
Add several at once and feel better, and you won't know which one did it.
Not much on any given day. No rush, no stimulant effect, no obvious moment. People who respond describe it as cumulative — steadier energy across the afternoon, workouts that feel slightly more productive after a couple of weeks, appetite that's less erratic.
A common early pattern is feeling good for a few days and then noticeably flat. That timing lines up with the point where the signal starts demanding materials.
| Parameter | Reported |
|---|---|
| Commonly reported dose | 5–10 mg |
| Frequency | 2–3x weekly |
| Also reported | Lower daily dosing |
| Cycle length | 4–8 weeks, then off |
| Estimated half-life | ~4–6 hours |
| Route | Subcutaneous |
| Phase 1 analog protocol | Daily, 30 days |
It degrades faster than most peptides, and poor storage is the most common reason a cycle does nothing at all.
Stable long-term. Keep vials sealed until you're ready to reconstitute.
Refrigerate immediately. Shorter usable window than most peptides.
Never leave reconstituted product at room temperature for long.
One vial at a time. Reconstituting several in advance wastes the later ones.
Injection site reactions are the headline. Redness, flushing, warmth, itching, sometimes small persistent bumps. This was common enough in the CB4211 trial to pause it in 2018 — researchers suspected some of the compound was lingering at the injection site rather than dispersing.
It appears to be a mast cell and histamine response rather than a true allergy. Injecting slowly, starting at the low end, rotating sites, and an antihistamine beforehand help some people. Other reported effects are mild: occasional post-injection fatigue, headache, appetite shifts early on.
Hives spread beyond the injection site, your face or throat swells, breathing changes, or you feel faint. That's systemic, not local — a different situation entirely.
Because this peptide degrades easily, supplier handling matters more here than almost anywhere else.
Lot number should match your vial. A generic PDF reused across the catalog isn't a COA.
The actual chart, not just a "99%" claim on a graphic. Standard spec is ≥99% purity.
Reported in EU/mg, typically under 0.1. Often missing — that absence is information.
If it arrives warm after days in transit, that's a real problem for this one.
No. It's sold as a research compound and has never been through a human clinical trial in its own right.
Common pattern. One plausible explanation is that the signal outran the supplies — see what it needs to work. Other possibilities: novelty wearing off, the histamine response, or something unrelated. Change one thing at a time to find out.
The fuel-switching half starts fast. The capacity half takes weeks. Most reports describe subtle shifts around weeks 2–4, with markers moving over 4–6 weeks.
Mast cell activation releasing histamine, most likely. It often settles after the first few injections. Injecting more slowly helps.
At moderate doses the effect is small. At higher doses, AMPK activation suppresses mTOR, which drives muscle protein synthesis.
People do. There's no human data on any combination, so nobody can tell you how they interact.
SS-31 targets the inner membrane of your mitochondria, where it binds a fat called cardiolipin to hold the energy machinery in alignment, reduce oxidative stress at its source, and preserve ATP output. It's the most clinically studied compound in the research-peptide space — and in 2025 it became the first mitochondria-targeted drug ever approved.
SS-31 is a four-amino-acid peptide (D-Arg-Dmt-Lys-Phe-NH₂) that concentrates inside mitochondria — specifically at the inner membrane, where energy production happens. It was discovered by Hazel Szeto's lab at Weill Cornell Medicine and developed as a drug under the name elamipretide.
Unlike almost everything else in this category, it has been through multiple Phase 2 and Phase 3 human trials. In September 2025 the FDA granted accelerated approval to elamipretide for Barth syndrome, a rare genetic mitochondrial disease — the first mitochondria-targeted therapeutic ever approved.
| Benefit | Description |
|---|---|
| Mitochondrial energy | Preserves electron-transport efficiency and ATP output, particularly when mitochondria are under stress. |
| Oxidative stress | Neutralizes superoxide and hydroxyl radicals at the inner membrane, where they're generated, rather than after they've dispersed. |
| Membrane integrity | Binds cardiolipin to maintain cristae structure — the folded architecture that holds the energy machinery in working order. |
| Cell survival | Reduces cytochrome-c release and caspase-3 activation in neuronal and cardiac cell models — the signaling that drives cells to die under stress. |
| Cardiac function | Studied for heart function and ischemia-reperfusion injury, where mitochondrial damage is a central driver. |
| Inflammation | Lowers pro-inflammatory markers including IL-1β and TNF-α in preclinical tissue models. |
Mitochondria generate energy along a chain of protein complexes embedded in their inner membrane. That membrane is folded into structures called cristae, and a phospholipid called cardiolipin holds the folds in shape and keeps the complexes properly assembled next to each other.
When cardiolipin is damaged — by age, disease, or oxidative stress — the architecture loosens. Electrons leak out of the chain instead of passing cleanly down it. Output drops, and the escaped electrons form reactive oxygen species, which damage more cardiolipin. It's a feedback loop.
SS-31 carries a positive charge that draws it into mitochondria, where it binds cardiolipin directly.
Cristae keep their shape and the transport complexes stay properly assembled.
A tighter chain means fewer escaped electrons, so fewer reactive species get made in the first place.
Energy output holds up better under metabolic or ischemic stress.
Less cytochrome-c escapes the membrane, which is the trigger for the cell's self-destruct pathway.
Think of a cell as a ship.
Down in the hull are the engine rooms — the mitochondria. Inside each one, the machinery is bolted to the walls in a very particular arrangement, and the whole thing is held together by gaskets.
Those gaskets are cardiolipin.
When they're new, everything sits tight. Power flows through the machinery cleanly, end to end, and comes out as usable energy.
But gaskets wear out. As they crack, the machinery shifts out of alignment and starts throwing sparks. You lose power — and worse, the sparks burn the gaskets around them. Which makes more sparks. Which burns more gaskets.
SS-31 is the repair crew for those gaskets. It goes straight down to the engine rooms, seals the leaks, and gets the machinery seated properly again. Power output steadies, and the sparks stop before they start.
SS-31 has better human evidence than nearly anything else in this category — and a more complicated record. The FDA approval covers Barth syndrome, a genetic disease affecting roughly 150 people in the United States that damages cardiolipin directly. It came through the accelerated pathway, based on improved knee-extensor strength — a marker considered likely to predict benefit rather than proof of it.
Trials in broader populations have not produced approvals. A Phase 3 in mitochondrial myopathy missed both primary endpoints across 218 patients, though the prespecified subgroup with nuclear-DNA mutations did improve on walking distance. A follow-up trial built specifically around that subgroup completed in late 2024; results haven't been published. Trials in heart failure missed their endpoint, and work in dry macular degeneration is ongoing.
Every human trial used 40–60 mg daily. Community protocols typically run 1–5 mg — roughly ten times lower.
Every trial enrolled people with diagnosed mitochondrial disease. None tested healthy adults for energy or longevity.
Entirely renally excreted. The approved label halves the dose in severe renal impairment.
3–4 hours, with almost no accumulation between daily doses. Timing consistency matters more than with a long-acting compound.
Not an occasional issue — the dominant adverse event across the whole clinical program.
Stabilizing the machinery does nothing if the parts it runs on are missing. See what it needs to work.
SS-31 protects the machinery. It doesn't supply what the machinery runs on. That's a different requirement from a compound that tells your body to build — this one is about operating supplies rather than construction materials.
Sealing the gaskets doesn't help if the fuel lines are empty or the parts are missing. Every item below is a physical component or cofactor of the electron transport chain that SS-31 is stabilizing.
The mobile electron carrier inside the chain SS-31 protects. If it's depleted, stabilizing the housing doesn't restore function — the carrier itself is what's missing. Absorbs better with fat.
The chain starts at Complex I, and NAD+ is what feeds it. No NAD+, no electrons entering the system. Poorly absorbed orally — NR or NMN are the usual route.
Converts to FAD, the cofactor for Complex II and the flavoproteins that hand electrons into the chain from fat metabolism.
Rarely mentioned, and it's the most direct one: cardiolipin — the exact molecule SS-31 binds — is built largely from linoleic acid. The target is made from dietary fat.
Iron-sulfur clusters do the actual electron handoffs through Complexes I, II, and III. Deficiency degrades the chain regardless of how stable the membrane is.
ATP functions in the body as Mg-ATP. Producing more ATP is only useful if there's magnesium to pair it with.
Reports skew toward steadier endurance and less of the flat, drained feeling that shows up under sustained physical or cognitive load. It isn't described as stimulating — there's no lift, no edge, nothing that arrives within an hour of injecting.
The most consistently reported sensation isn't an effect at all — it's the injection site. Warmth, redness, itching, occasionally a small firm bump that lingers. Expect that rather than being surprised by it.
| Parameter | Reported |
|---|---|
| Clinical trial dose | 40 mg daily |
| Follow-up trial dose | 60 mg daily |
| Commonly reported dose | 1–5 mg |
| Frequency | Daily |
| Cycle length | Trials ran continuously |
| Half-life | 3–4 hours |
| Route | Subcutaneous |
Stable long-term. Keep sealed until you're ready to reconstitute.
Refrigerate at 2–8°C. More forgiving than MOTS-c, but not indefinite.
Repeated freeze-thaw cycles degrade it. Aliquot if you're freezing reconstituted product.
Solution should be clear. Particulates or persistent cloudiness mean don't use it.
Injection site reactions dominate. Redness, warmth, itching, and small firm bumps that can persist. This is the most common adverse event in every trial of this compound, and it's common enough that it has been studied in its own right.
Research found that elamipretide activates MRGPRX2, a receptor on mast cells. Triggering it releases histamine and drives local inflammation. That makes it a direct pharmacological effect rather than an allergy or a contamination problem.
In a Phase 1 crossover, topical mometasone applied before injecting significantly reduced reactions — without changing plasma levels of the drug.
Ice reduced pain, but also lowered peak concentration and total exposure. It costs you some of the dose.
Standard practice, and it matters more here given how persistent the bumps can be.
Rapid injection tends to provoke a stronger local response.
Beyond the injection site, tolerability was described as good across the clinical program, including long-term use past three years in the Barth extension study. Other reported effects are mild: headache, nausea, occasional dizziness.
Hives spread beyond the injection site, your face or throat swells, breathing changes, or you feel faint. That's systemic, not local — a different situation entirely.
SS-31 is unusual in that an approved pharmaceutical version exists. What's sold as a research compound is not that product, and is only as good as the supplier.
Lot number should match your vial. A generic PDF reused across the catalog isn't a COA.
The actual chart, not just a "99%" claim on a graphic. Standard spec is ≥99% purity.
Reported in EU/mg, typically under 0.1. Often missing — that absence is information.
Peptides degrade with heat. If it arrives warm after days in transit, that matters.
The pharmaceutical version, elamipretide, was approved in September 2025 for Barth syndrome — one rare genetic disease affecting about 150 people in the US. SS-31 sold as a research compound is a different thing and is not approved for human use.
Trials used 40–60 mg daily in people with genetic mitochondrial disease under clinical monitoring. Community protocols run roughly ten times lower. Nobody has published a study at the lower amounts, so the gap is unexplained rather than resolved.
SS-31 activates MRGPRX2 on mast cells, which releases histamine locally. It's a direct effect of the compound, not an allergy. Topical corticosteroid before injecting has been shown to help.
Protection is harder to feel than stimulation — you'd be noticing an absence of decline rather than a positive effect. Trials measured over weeks to months, not days.
The clinical trials dosed continuously for 24 weeks and beyond, some out past three years. Community protocols commonly cycle 8 weeks on and off, but that convention doesn't come from trial data.
People do. There's no human data on any combination, so nobody can tell you how they interact.